James N George

List of Publications by Year
in descending order

126 papers	6,914 citations	147801 31 h-index	60623 81 g-index
126 all docs	126 docs citations	126 times ranked	4464 citing authors

#	Article	IF	Citations
1	Syndromes of Thrombotic Microangiopathy. New England Journal of Medicine, 2014, 371, 654-666.	27.0	972
2	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5.2	684
3	ADAMTS13 activity in thrombotic thrombocytopenic purpuraâ€“hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 2003, 102, 60-68.	1.4	649
4	Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2006, 354, 1927-1935.	27.0	509
5	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	1.4	477
6	How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood, 2010, 116, 4060-4069.	1.4	415
7	Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125, 616-618.	1.4	282
8	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600.	5.2	207
9	Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology American Society of Hematology Education Program, 2009, 2009, 153-158.	2.5	203
10	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	1.5	193
11	Platelet Counts during Pregnancy. New England Journal of Medicine, 2018, 379, 32-43.	27.0	157
12	Improved quality of life for romiplostimâ€treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placeboâ€controlled trials. British Journal of Haematology, 2009, 144, 409-415.	2.5	150
13	The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood, 2015, 125, 1526-1531.	1.4	102
14	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094.	1.4	99
15	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	3.5	99
16	Hereditary Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 381, 1653-1662.	27.0	93
17	Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology American Society of Hematology Education Program, 2015, 2015, 644-648.	2.5	79
18	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	3.5	69

#	Article	IF	Citations
19	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178.	1.4	68
20	Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care. American Journal of Hematology, 2003, 74, 161-169.	4.1	64
21	Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. Journal of Oncology Practice, 2016, 12, 523-530.	2.5	64
22	Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 2017, 1, 2075-2082.	5.2	61
23	Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, 709-714.	4.1	59
24	Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 381, 92-94.	27.0	59
25	Platelets: Thrombotic Thrombocytopenic Purpura. Hematology American Society of Hematology Education Program, 2002, 2002, 315-334.	2.5	58
26	Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. Annals of Medicine, 1998, 30, 38-44.	3.8	54
27	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Diagnosis and management. Journal of Clinical Apheresis, 1998, 13, 120-125.	1.3	50
28	Diversity and severity of adverse reactions to quinine: A systematic review. American Journal of Hematology, 2016, 91, 461-466.	4.1	43
29	Overlapping Features of Thrombotic Thrombocytopenic Purpura and Systemic Lupus Erythematosus. Southern Medical Journal, 2007, 100, 512-514.	0.7	40
30	TTP: long-term outcomes following recovery. Hematology American Society of Hematology Education Program, 2018, 2018, 548-552.	2.5	40
31	Thrombotic thrombocytopenic purpura?hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report. , 1999, 61, 268-270.		38
32	A disease-specific measure of health-related quality of life in adults with chronic Immune Thrombocytopenic Purpura: Psychometric testing in an open-label clinical trial. Clinical Therapeutics, 2007, 29, 950-962.	2.5	38
33	Drugâ€induced thrombocytopenia: 2019 Update of clinical and laboratory data. American Journal of Hematology, 2019, 94, E76-E78.	4.1	34
34	Drug-Induced Thrombocytopenia: An Updated Systematic Review. Annals of Internal Medicine, 2001, 134, 346.	3.9	31
35	Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood, 2021, 137, 3563-3575.	1.4	31
36	Drugâ€induced thrombotic microangiopathy: An updated systematic review, 2014â€2018. American Journal of Hematology, 2018, 93, E241-E243.	4.1	30

#	Article	IF	Citations
37	Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets. Cytometry, 1994, 17, 287-293.	1.8	29
38	Measuring <scp>ADAMTS</scp>13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?. Transfusion, 2015, 55, 11-13.	1.6	29
39	Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura. Journal of Intensive Care Medicine, 2007, 22, 82-91.	2.8	28
40	Unintentional platelet removal by plasmapheresis. Journal of Clinical Apheresis, 2001, 16, 55-60.	1.3	27
41	Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovahâ€™s Witness experience. Blood Advances, 2017, 1, 2161-2165.	5.2	25
42	The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Advances, 2018, 2, 1510-1516.	5.2	24
43	Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. American Journal of Hematology, 2020, 95, E76-E77.	4.1	24
44	Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%â€20%. American Journal of Hematology, 2017, 92, E644-E646.	4.1	20
45	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a program for patient care, education and research. Transfusion, 2004, 44, 1384-1392.	1.6	18
46	Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion, 2017, 57, 2532-2538.	1.6	18
47	Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. American Journal of Hematology, 2019, 94, E172-E174.	4.1	17
48	Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy. American Journal of Hematology, 2019, 94, E8-E11.	4.1	17
49	After the Partyâ€™s Over. New England Journal of Medicine, 2017, 376, 74-80.	27.0	16
50	Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura. Pediatric Blood and Cancer, 2019, 66, e27737.	1.5	16
51	Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. American Journal of Hematology, 2021, 96, 1655-1665.	4.1	16
52	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. Blood, 2010, 116, 68-68.	1.4	15
53	Drug-Induced Thrombocytopenia. Drug Safety, 2012, 35, 693-694.	3.2	14
54	Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?. Lancet, The, 2015, 386, 1012.	13.7	14

#	Article	IF	Citations
55	Immune Thrombocytopenia Treatment. New England Journal of Medicine, 2021, 385, 948-950.	27.0	14
56	Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura. American Journal of Hematology, 2020, 95, E316-E318.	4.1	13
57	Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. Pediatric Blood and Cancer, 2021, 68, e28949.	1.5	13
58	Deletion of platelet CLEC-2 decreases GPIba-mediated integrin aIIb3 activation and decreases thrombosis in TTP. Blood, 2022, , .	1.4	13
59	Idiopathic thrombocytopenic purpura in adults: current issues for pathogenesis, diagnosis and management. The Hematology Journal, 2004, 5, S12-S14.	1.4	12
60	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologistâ€“oncologists. Journal of Thrombosis and Thrombolysis, 2018, 46, 24-30.	2.1	11
61	TTP: the evolution of clinical practice. Blood, 2021, 137, 719-720.	1.4	11
62	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency.. Blood, 2004, 104, 857-857.	1.4	11
63	Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. Kidney International Reports, 2017, 2, 1088-1095.	0.8	9
64	The Evidence-Based Analysis of Treatment for Chronic Myeloid Leukemia: An Introduction to Its Methods and Clinical Implications. Blood, 1999, 94, 1515-1516.	1.4	8
65	Depression in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2016, 91, E462-3.	4.1	8
66	Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion, 2019, 59, 921-926.	1.6	8
67	Forecasting the future for patients with hereditary TTP. Blood, 2012, 120, 243-244.	1.4	7
68	The importance of clinical judgment for the diagnosis of thrombotic thrombocytopenic purpura. Transfusion, 2017, 57, 2558-2561.	1.6	7
69	Quebec platelet syndrome: from the bench to the family. Blood, 2004, 104, 8-8.	1.4	6
70	The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.. Blood, 2007, 110, 277-277.	1.4	6
71	Thrombotic thrombocytopenic purpura masquerading as preclampsia with severe features at 13â€‰weeks' gestation. American Journal of Hematology, 2020, 95, 1216-1220.	4.1	5
72	Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).. Blood, 2008, 112, 3415-3415.	1.4	5

#	Article	IF	Citations
73	For low platelets, how low is dangerous?. Cleveland Clinic Journal of Medicine, 2004, 71, 277-278.	1.3	5
74	Interferon-induced thrombotic microangiopathy. Blood, 2016, 128, 2753-2754.	1.4	4
75	Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshawâ€Schulman syndrome). Transfusion, 2017, 57, 3058-3062.	1.6	4
76	Platelet Counts during Pregnancy. New England Journal of Medicine, 2018, 379, 1581-1582.	27.0	4
77	Embolic stroke of undetermined source in a young woman. American Journal of Hematology, 2019, 94, 1044-1048.	4.1	4
78	Hypertension in patients with hereditary thrombotic thrombocytopenic purpura. EJHaem, 2020, 1, 342-343.	1.0	4
79	A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura. Blood, 2016, 128, 133-133.	1.4	4
80	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	2.5	4
81	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789.	1.4	4
82	Quinine: common remedy, serious reactions, new insights. Blood, 2006, 108, 782-783.	1.4	3
83	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes.. Blood, 2004, 104, 858-858.	1.4	3
84	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 1067-1067.	1.4	3
85	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 1311-1311.	1.4	3
86	The Prevalence of Immune Thrombocytopenic Purpura (ITP).. Blood, 2008, 112, 1277-1277.	1.4	3
87	Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.. Blood, 2008, 112, 3422-3422.	1.4	3
88	Controlling chronic TTP. Blood, 2005, 106, 1896-1896.	1.4	2
89	Congenital TTP: toward a turning point. Blood, 2019, 133, 1615-1617.	1.4	2
90	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities.. Blood, 2004, 104, 856-856.	1.4	2

#	Article	IF	Citations
91	First Symptoms In Idiopathic Thrombotic Thrombocytopenic Purpura (TTP): What Are They and When Do They Occur?.. Blood, 2010, 116, 1427-1427.	1.4	2
92	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. Blood, 2007, 110, 1317-1317.	1.4	2
93	Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Frequency, Presenting Features, and Clinical Outcomes.. Blood, 2007, 110, 1315-1315.	1.4	2
94	Longâ€term outcomes of healthâ€related quality of life following diverse thrombotic microangiopathy syndromes. American Journal of Hematology, 2016, 91, E278-9.	4.1	1
95	A postpartum perfect storm. American Journal of Hematology, 2017, 92, 1105-1110.	4.1	1
96	Thrombotic thrombocytopenic purpuraâ€"hemolytic uremic syndrome (TTPâ€HUS) following treatment with deoxycoformycin in a patient with cutaneous Tâ€cell lymphoma (Sezary syndrome): A case report. American Journal of Hematology, 1999, 61, 268-270.	4.1	1
97	Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia. Blood, 2018, 132, 130-130.	1.4	1
98	Detecting Drugs That Cause Thrombocytopenia: A Comparison of Three Methods: Tests for Drug-Dependent Anti-Platelet Antibodies (DDab), Published Case Reports, and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database.. Blood, 2007, 110, 2087-2087.	1.4	1
99	The Frequency of Rheumatic Disease Autoantibodies in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 2090-2090.	1.4	1
100	Documentation of Fatigue In Patients with Immune Thrombocytopenic Purpura (ITP) and Its Association with Autonomic Dysfunction. Blood, 2010, 116, 570-570.	1.4	1
101	International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) â€" Upshaw-Schulman Syndrome. Blood, 2012, 120, 4654-4654.	1.4	1
102	Thrombotic Thrombocytopenic Purpura (TTP) Patient Attitudes Regarding Depression Management: a Qualitative Study. Blood, 2014, 124, 203-203.	1.4	1
103	Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP). Blood, 2008, 112, 4707-4707.	1.4	1
104	Incidence, Age, and Gender of Children with Thrombotic Thrombocytopenic Purpura (TTP) Associated with Severe, Acquired ADAMTS13 Deficiency.. Blood, 2012, 120, 2196-2196.	1.4	1
105	Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients. Blood, 2018, 132, 376-376.	1.4	1
106	The AuthorsÊ¼ Reply. Drug Safety, 2009, 32, 708.	3.2	0
107	Treatment of Immune Thrombocytopenia in Adults: Version 2019. Mayo Clinic Proceedings, 2019, 94, 2161-2163.	3.0	0
108	Preventable deaths during initial episodes of acquired Thrombotic Thrombocytopenic Purpura: Past and future. American Journal of Hematology, 2019, 94, E242-E244.	4.1	0

#	Article	IF	Citations
109	Cyclosporine Alone for the Treatment of Early Recurrences of TTP.. Blood, 2005, 106, 1236-1236.	1.4	0
110	ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2005, 106, 60-60.	1.4	0
111	Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.. Blood, 2005, 106, 1235-1235.	1.4	0
112	Detecting Drugs That Cause Thrombocytopenia: A Comparison of Published Case Reports and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database.. Blood, 2006, 108, 462-462.	1.4	0
113	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases.. Blood, 2006, 108, 1062-1062.	1.4	0
114	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. Blood, 2007, 110, 1302-1302.	1.4	0
115	Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.. Blood, 2008, 112, 2299-2299.	1.4	0
116	What Level of Platelet Count and Symptoms Trigger Referral of Patients with Thrombocytopenia from Primary Care Physicians to Hematologists?. Blood, 2008, 112, 4692-4692.	1.4	0
117	Are Patients Who Have Recovered From ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) at Risk for Developing Systemic Lupus Erythematosus (SLE)?. Blood, 2010, 116, 2519-2519.	1.4	0
118	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. Blood, 2010, 116, 3694-3694.	1.4	0
119	The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia.. Blood, 2010, 116, 3691-3691.	1.4	0
120	Quinine-Induced Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Characteristic Clinical Presentation and High Risk for Chronic Kidney Disease (CKD). Blood, 2011, 118, 2216-2216.	1.4	0
121	A case report of long-term complete remission following cessation of romiplostim dosing in a previously severe ITP patient.. Journal of Clinical Oncology, 2012, 30, e17001-e17001.	1.6	0
122	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. Blood, 2012, 120, 1094-1094.	1.4	0
123	Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry. Blood, 2021, 138, 770-770.	1.4	0
124	Hybrid Cross-Discipline, Interactive Curriculum to Nurture the Training Experience for Hematology-Oncology Trainees. Blood, 2021, 138, 2981-2981.	1.4	0
125	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at Enrolment until 2017. Hamostaseologie, 2020, 40, .	1.9	0
126	Thrombotic thrombocytopenic purpura: Crossing to safety. Transfusion, 2022, 62, 1166-1170.	1.6	0